CLOUDIMPP: Closed-Loop O2 Use During Invasive Mechanical Ventilation Of Pediatric Patients

Sponsor
Dr. Behcet Uz Children's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05714527
Collaborator
Hamilton Medical AG (Industry)
30
4
2
3.9
7.5
1.9

Study Details

Study Description

Brief Summary

During mechanical ventilation (MV) hypoxemic or hyperoxemic events should be carefully monitored and a quick response should be provided by the caregiver at the bedside. Pediatric mechanical ventilation consensus conference (PEMVECC) guidelines suggest to measure SpO2 in all ventilated children and furthermore to measure partial arterial oxygen pressure (PaO2) in moderate-to-severe disease. There were no predefined upper and lower limits for oxygenation in pediatric guidelines, however, Pediatric acute lung injury consensus conference PALICC guidelines proposed SpO2 between 92 - 97% when positive end-expiratory pressure (PEEP) is smaller than 10 cm H2O and SpO2 of 88 - 92% when PEEP is bigger or equal to 10 cm H2O. For healthy lung, PEMVECC proposed the SpO2>95% when breathing a FiO2 of 21%. As a rule of thumb, the minimum fraction of inspired O2 (FiO2) to reach these targets should be used. A recent Meta-analyze showed that automated FiO2 adjustment provides a significant improvement of time in target saturations, reduces periods of hyperoxia, and severe hypoxia in preterm infants on positive pressure respiratory support. This study aims to compare the closed-loop FiO2 controller with conventional control of FiO2 during mechanical ventilation of pediatric patients

Condition or Disease Intervention/Treatment Phase
  • Device: Close-loop FiO2 controller
  • Device: Conventional
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Closed-Loop O2 Use During Invasive Mechanical Ventilation Of Pediatric Patients (CLOUDIMPP)- a Randomized Cross-over Study
Anticipated Study Start Date :
Jan 30, 2023
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Close-loop FiO2 Controller

Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.

Device: Close-loop FiO2 controller
Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.

Active Comparator: Conventional

Conventional FiO2 adjustment by the clinician according to SpO2 values

Device: Conventional
Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.

Outcome Measures

Primary Outcome Measures

  1. Percentage of time spent in optimal SpO2 range [2 hours]

    The optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.

Secondary Outcome Measures

  1. Percentage of time spent in suboptimal SpO2 range [2 hours]

    SpO2 values outside the optimal range but still within an acceptable limit (2-3 percent above and below the optimal range)

  2. Mean FiO2 [2 hours]

    Mean fraction of inspired oxygen

  3. Mean SpO2/FiO2 [2 hours]

    Mean SpO2/FiO2

  4. Number of manual adjustments [2 hours]

    Frequency of manual adjustments of FiO2

  5. Number of alarms [2 hours]

    Frequency of alarms

  6. Percentage of time with SpO2 signal available [2 hours]

    Time with SpO2 signal available

  7. Percentage of time with SpO2 below 88 and 85 percent [2 hours]

    Duration of time with SpO2 <85 percent and <88 percent, respectively

  8. Number of events with SpO2 below 88 and 85 percent [2 hours]

    Frequency of SpO2 decreases <85 percent and <88 percent, respectively

  9. Percentage of time with FiO2 below 40 percent, 60 percent and 100 percent [2 hours]

    Percentage of time that FiO2 is <40 percent, 60 percent and 100 percent, respectively

  10. Total oxygen use [2 hours]

    Volume of total oxygen used (in L)

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pediatric patients older than 1 month and younger than18 years of age; hospitalized at the PICU with the intention of treatment with IMV at least for the upcoming 5 hours

  • Requiring FiO2 ≥ 25% to keep SpO2 in the target ranges defined by the clinician

  • Written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation

Exclusion Criteria:
  • Patient with indication for immediate noninvasive ventilation (NIMV), High flow oxygen therapy (HFOT)

  • Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine > 1 mg/h

  • Low quality on the SpO2 measurement using finger and ear sensor (quality index below 60% on the SpO2 sensor, which is displayed by a red or orange colour bar)

  • Severe acidosis (pH ≤ 7.25)

  • Pregnant woman

  • Patients deemed at high risk for the need of non-invasive mechanical ventilation within the next 5 hours

  • Patients deemed at high risk for the need of transportation from PICU to another ward, diagnostic unit or any other hospital

  • Diseases or conditions which may affect transcutaneous SpO2 measurement such as chronic or acute dyshemoglobinemia: methemoglobinemia, carbon monoxide (CO) poisoning, sickle cell disease

  • Formalized ethical decision to withhold or withdraw life support

  • Patient included in another interventional research study under consent

  • Patient already enrolled in the present study in a previous episode of acute respiratory failure

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aydin Obstetric and pediatrics Hospital Aydın Turkey 09020
2 Erzurum Regional Research and Training Hospital Erzurum Turkey 25180
3 Cam Sakura Research and Training Hospital Istanbul Turkey 34001
4 The Health Sciences University Izmir Behçet Uz Child Health and Diseases Research and Training Hospital Izmir Turkey 35200

Sponsors and Collaborators

  • Dr. Behcet Uz Children's Hospital
  • Hamilton Medical AG

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hasan ağın, Professor, Dr. Behcet Uz Children's Hospital
ClinicalTrials.gov Identifier:
NCT05714527
Other Study ID Numbers:
  • 2022/750
First Posted:
Feb 6, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hasan ağın, Professor, Dr. Behcet Uz Children's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2023